Anti MAP1B paraneoplastic syndrome
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anti MAP1B paraneoplastic syndrome. Small cell lung cancer (SCLC) in about 70%, Squamous cell carcinoma. Fully referenced neurology checklist.
Primary cancers
- Small cell lung cancer (SCLC) in about 70%
- Squamous cell carcinoma
- Renal cell carcinoma
- Large cell anaplastic lymphoma
- Non-small cell lung cancer
Presentations
Locked: subscribe to see this section.
Peripheral neuropathy: types
Locked: subscribe to see this section.
Peripheral neuropathy: features and course
Locked: subscribe to see this section.
Peripheral neuropathy: treatment
Locked: subscribe to see this section.
Acronyms
Locked: subscribe to see this section.
Synonym
Locked: subscribe to see this section.
References
- Zekeridou A, Kryzer T, Guo Y, et al. Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology 2019; 93:e815-e822.
- Jitprapaikulsan J, Klein CJ, Pittock SJ, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. JNNP 2020; 91:328-330.
- Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol 2017; 81:266-277.
